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Abstract 1 
G protein-coupled receptors (GPCRs) are the largest family of membrane receptors and mediate the 2 
effects of numerous hormones and neurotransmitters. The nearly 1,000 GPCRs encoded by the human 3 
genome regulate virtually all physiological functions and are implicated in the pathogenesis of prevalent 4 
human diseases such as thyroid disorders, hypertension or Parkinson´s disease. As a result, 30 to 50% of 5 
all currently prescribed drugs are targeting these receptors. Once activated, GPCRs induce signals at the 6 
cell surface. This is often followed by internalization, a process that results in the transfer of receptors 7 
from the plasma membrane to membranes of the endosomal compartment. Internalization was initially 8 
thought to be mainly implicated in signal desensitization, a mechanism of adaptation to prolonged 9 
receptor stimulation. However, several unexpected functions have subsequently emerged. Most 10 
notably, accumulating evidence indicates that internalization can induce prolonged receptor signaling on 11 
intracellular membranes, which is apparently required for at least some biological effects of hormones 12 
like TSH, LH and adrenaline. These findings reveal an even stronger connection between receptor 13 
internalization and signaling than previously thought. Whereas new studies are just beginning to reveal 14 
an important physiological role for GPCR signaling after internalization and ways to exploit it for 15 
therapeutic purposes, future investigations will be required to explore its involvement in human disease. 16 
 17 
Keywords 18 
GPCR, cAMP, receptor internalization, TSH, PTH, LH, endosomal signaling. 19 
 20 
Abbreviations 21 
G protein-coupled receptor (GPCR), protein kinase A (PKA), cyclic adenosine monophosphate (cAMP), 22 
mitogen-activated protein kinase (MAPK), thyroid stimulating hormone (TSH), parathyroid hormone 23 
(PTH), protein kinase A (PKA), neurokinin (NK), clathrin-mediated endocytosis (CME), clathrin-coated pits 24 
(CCPs). 25 
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Introduction 1 
G protein-coupled receptors (GPCRs), with a share of almost 4% of the human genome [1], constitute 2 
the largest family of receptors that allow cells to sense extracellular stimuli [2, 3]. These external stimuli 3 
range from sensory cues like light, odorants and tastants to small-molecule neurotransmitters, peptides 4 
and hormones [2, 3]. This high diversity underscores the fundamental role that GPCRs play in the 5 
function of the endocrine, nervous, cardiovascular, sensory and immune systems. 6 
The main initial steps of GPCR activation and signaling have been elucidated in detail [2, 4]. These events 7 
are initiated by binding of an agonist to a receptor, which triggers a series of conformational changes in 8 
the receptor that culminate in its activation. The activated receptor, in turn, binds to and activates 9 
heterotrimeric G proteins, which are composed of an α, β and γ subunit and exist in different isoforms. 10 
The α and βγ subunit finally modulate the activity of membrane-localized effectors, including ion 11 
channels and enzymes like phospholipase Cβ (PLCβ) and adenylyl cyclase. 12 
A classic example of the role of these receptors in physiology is their involvement in the regulation of 13 
heart contractility. β-adrenergic receptors located on the surface of cardiomyocytes mediate the 14 
positive ionotropic and chronotropic effects of adrenalin and noradrenalin, released upon sympathetic 15 
activation. Binding of adrenalin or noradrenalin to these receptors, which are coupled to the Gs protein, 16 
activate adenylyl cyclases to produce cAMP, which stimulates protein kinase A (PKA). PKA, in turn, 17 
phosphorylates different molecules involved in cardiac contractility, including L-type Ca
2+
 channels, 18 
phospholamban and troponin I, ultimately leading to enhanced cardiomyocyte contractility [5]. In 19 
addition, cAMP directly promotes the opening of pacemaker (HCN) channels in the conductive tissue, 20 
thus increasing heart rate [6, 7]. Parasympathetic activation counteracts these effects via release of 21 
acetylcholine, which binds to muscarinic (M2) receptors coupled to Gi/o, thus inhibiting adenylyl cyclase 22 
activation. In addition, the βγ subunits released upon Gi/o activation stabilize the membrane potential via 23 
activating potassium (GIRK) channels in the conductive tissue [8-12]. In the endocrine system, GPCRs 24 
play an essential role as receptors for several hormones, hypothalamic releasing factors and local 25 
modulators. All major known hypothalamic releasing (TRH, GnRH, CRH, GHRH) and inhibiting 26 
(somatostatin, dopamine) hormones act via specific GPCRs [13-17]. With the exception of GH and PRL, 27 
anterior (TSH, LH, FSH, ACTH, MSH) and posterior (vasopressin, oxytocin) pituitary hormones also signal 28 
through activation of GPCRs [18]. For an extensive discussion of the specific roles of GPCRs and G 29 
proteins in human physiology we refer the reader to the comprehensive review by Wettschureck and 30 
Offermanns [19]. 31 
 32 
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 1 
Mechanisms of GPCR internalization 2 
Like for other types of receptors, prolonged agonist stimulation often leads to GPCR internalization, 3 
which can occur via different pathways [2, 20-23]. Of these pathways, clathrin-mediated endocytosis 4 
(CME) is the best characterized and arguably most relevant one (Figure 1) [2, 20-23]. The first molecular 5 
event involved in GPCR internalization is the binding of a family of G protein-coupled receptor kinases 6 
(GRKs) to an agonist-occupied receptor, which phosphorylate multiple intracellular serine and threonine 7 
residues located in the 3rd intracellular loop or at the C-terminus of the receptor [24-27]. This is followed 8 
by binding of arrestins to the phosphorylated receptor, which plays a major role in both fast signal 9 
desensitization and receptor internalization [24, 26]. On the one hand, arrestins compete with G 10 
proteins for binding to the receptor, thus leading to signal desensitization. On the other hand, they 11 
promote receptor internalization via interacting with key proteins involved in the assembly of clathrin-12 
coated pits (CCPs) such as the clathrin heavy chain and the clathrin adaptor protein AP2 [28, 29]. This 13 
leads to the recruitment of GPCRs into CCPs, which detach form the plasma membrane in a process that 14 
requires the small GTPase dynamin [30]. Receptors are then rapidly transferred to early endosomes, 15 
from where they can follow either of two main trafficking pathways [21, 31]. Some GPCRs are sorted out 16 
in the endosomal compartment, where they are dephosphorylated, to be then recycled back to the 17 
plasma membrane. Others are directed to lysosomes where they are degraded, leading to receptor 18 
downregulation [24, 26]. 19 
 20 
Role of receptor internalization in MAPK signaling 21 
While rapid desensitization was shown to occur before receptor internalization and be mediated by 22 
receptor phosphorylation and β-arrestin recruitment, it also began to emerge that β-arrestin 23 
recruitment and receptor internalization might also exert other functions. In experiments using a 24 
dominant-negative dynamin mutant, Daaka et al. showed that receptor internalization is required for 25 
efficient ERK activation in response to β2-adrenergic receptor stimulation [32]. Subsequently, it was 26 
shown that β-arrestins can bind several components of mitogen-activated protein kinase (MAPK) 27 
pathways [33, 34], thus promoting G protein-independent MAPK signaling. Since some GPCR are found 28 
on early endosomes in complex with β-arrestins, it has been suggested that these events result in 29 
endosomal MAPK signaling (Figure 1) [35]. Intriguingly, the activation of arrestin-bound ERK has been 30 
shown to favor cytoplasmic vs. nuclear effects of MAPK activation by preventing ERK translocation to 31 
the nucleus [34, 36]. However, the β-arrestin dependent activation of MAPKs can also occur while the 32 
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receptors are still located on the plasma membrane. Thus, it remains to be clarified what is the relative 1 
contribution of cell surface vs. endosomal MAPK signaling. Moreover, some GPCRs that are poorly 2 
internalized are nevertheless able to efficiently induce MAPK signaling. This can be at least partially 3 
explained by the existence of other mechanisms leading to MAPK activation. Yet another possible 4 
explanation for these findings comes from a recent study on the β1-adrenergic receptor − which 5 
internalizes poorly upon agonist stimulation − indicating that receptor activation can lead to recruitment 6 
of β-arrestin to CCPs and MAPK signaling from CCPs in the absence of receptors [37]. 7 
 8 
New paradigm of GPCR signaling from intracellular compartments 9 
Although classical, G protein-dependent signaling has long been believed to be restricted to the plasma 10 
membrane, studies performed in the last ten years have provided strong evidence that internalized 11 
GPCRs can continue signaling on intracellular membranes (Figure 1). A first indication came from 12 
experiments on the Ste2 receptor, which is implicated in pheromone signaling in yeast [38]. 13 
Subsequently, our group and that of Jean-Pierre Vilardaga independently showed that the TSH and PTH 14 
receptors induce a persistent phase of cAMP production after internalization, which could be prevented 15 
by interfering with CME [39, 40]. Signaling by internalized TSH receptors was shown to differ from the 16 
one occurring at the plasma membrane in that it was required for efficient phosphorylation of the 17 
vasodilator-stimulated phosphoprotein (VASP) and actin depolymerization in response to TSH, which is 18 
involved in thyroglobulin reuptake and, thus, in thyroid hormone release [39]. In the case of the PTH 19 
receptor, signaling was shown to be turned off by retromer − which mediates retrograde trafficking 20 
from endosomes to the trans-Golgi network − and endosomal acidification [41, 42]. These findings 21 
challenged the classical model of GPCR signaling by indicating that G protein signaling can also occur on 22 
intracellular membranes. They also pointed to early endosomes, in the case of the PTH receptor, and the 23 
Golgi/trans-Golgi network, in the case of the TSH receptor, as likely sites of intracellular GPCR signaling 24 
(Figure 1). 25 
Further important evidence for G protein signaling on early endosomes has been subsequently obtained 26 
for the β2-adrenegic receptor using fluorescently-tagged conformation-sensitive nanobodies selectively 27 
recognizing the active receptor and Gs protein [43].  28 
More recently, our group used a combination of sensors based fluorescence resonance energy transfer 29 
(FRET) and a nanobody recognizing the active Gs protein to localize the subcellular compartment where 30 
endogenous TSH receptors are signaling in primary thyroid cells [44]. We found that the TSH receptor 31 
co-internalizes with TSH and traffics retrogradely to the trans-Golgi network, where it activates an 32 
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endogenous pool of Gs protein. This leads to a delayed phase of local cAMP production and PKA 1 
activation at a critical position near the nucleus, which appears required for efficient CREB 2 
phosphorylation and gene transcription in response to TSH [44]. In contrast to previous observations 3 
with the PTH receptor, however, retromer was found to promote persistent TSH receptor signaling [44]. 4 
A requirement of receptor internalization for gene transcription has also been demonstrated for the β2 5 
adrenergic receptor [45]. Moreover, signaling in the Golgi complex has also been demonstrated for 6 
the β1-adrenergic receptor [46]. However, in the case of the β1-adrenergic receptor, it has been 7 
suggested that adrenalin, which is hydrophilic, crosses cellular membranes via the organic cation 8 
transporter 3 (OCT3) and reaches a pool of β1-adrenergic receptors that reside in the Golgi complex [46]. 9 
In the meantime, signaling at intracellular membranes has been reported for several GPCRs, including 10 
the dopamine D1 receptor [47], vasopressin V2 receptor [48], glucagon-like peptide 1 (GLP1) receptor 11 
[49], pituitary adenylate cyclase activating polypeptide 1 (PACAP1) receptor [50] and glucose-dependent 12 
insulinotropic peptide (GIP) receptor [51]. 13 
A question left open by these studies was related to the apparent contrasting role of β-arrestins, which 14 
have a well-established role in signal desensitization and, at the same time, have been suggested to 15 
promote endosomal signaling. Intriguingly, recent structural studies indicate that β-arrestins can engage 16 
with two different domains of GPCRs, i.e. with either the C-tail or the seven-transmembrane core [52]. 17 
Moreover, a complex consisting of a receptor with the G protein bound to its seven-transmembrane 18 
core and β-arrestin 1 simultaneously bound to its C-tail has been directly observed by cry-electron 19 
microscopy [53]. 20 
All these studies suggest the existence of multiple intracellular locations for GPCR signaling (Figure 1). 21 
Some receptors, like the PTH and the β2-adrenergic receptor, seem to signal prevalently from early 22 
endosomes. In contrast, the TSH and the β1-adrennergic receptor signal on membranes of the 23 
Golgi/trans-Golgi network. Furthermore, there is evidence for GPCR signaling at other intracellular 24 
compartments such as the nuclear envelope [54] and, more recently, mitochondria. Indeed, cannabinoid 25 
CB1 receptors have been shown to be located on brain mitochondrial membranes, where they have 26 
been suggested to play a role in the amnesic effects of cannabinoids [55]. Similarly, melatonin has been 27 
shown to be produced inside neuronal mitochondria, where it activates local MT1 receptors [56]. The 28 
resulting signaling prevents stress-mediated cytochrome c release and caspase activation, thus 29 
contributing to melatonin neuroprotective effects [56]. Although we are only beginning to understand 30 
the implications of such a high degree of spatial control and complexity in GPCR signaling, it is likely that 31 
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these mechanisms play an important role in allowing to discriminate among the multitude of 1 
extracellular signals that converge on a single cell. 2 
 3 
Role of receptor internalization and trafficking in physiology and disease 4 
Consistent with their crucial role of in GPCR signaling, receptor internalization and trafficking are deeply 5 
implicated in human physiology and, most likely, also in disease. A first important aspect regards the 6 
correct subcellular localization of receptors. Indeed, genetic mutations affecting receptor trafficking and 7 
causing reduced cell surface localization of receptors are known to be implicated in various human 8 
diseases, such as TSH resistance, familial idiopathic hypogonadotropic hypogonadism, Leydig cell 9 
hypoplasia or familial glucocorticoid deficiency [57]. 10 
With the recent demonstration that GPCRs can continue signaling after internalization, GPCR signaling at 11 
intracellular sites is also emerging as an important aspect of GPCR biology with implications in 12 
physiology and disease. 13 
For the TSH receptor, signaling at the Golgi/trans-Golgi network appears required for both rapid effects 14 
of TSH − such as actin depolymerization, which is implicated in thyroglobulin reuptake and, thus, thyroid 15 
hormone release − and late ones, such as those on gene transcription. Continued signaling by TSH 16 
receptors after internalization might contribute to hyperthyroidism in Grave´s disease, where 17 
autoantibodies chronically activate the TSH receptor. Moreover, it might play a role in the pathogenesis 18 
of toxic thyroid adenomas and congenital/familial non-autoimmune hyperthyroidism, which are caused 19 
by activating TSH receptor mutations that are often associated with intracellular receptor accumulation 20 
[58, 59].  21 
For the PTH receptor, which plays a critical role in regulating Ca2+ homeostasis and bone turnover and is 22 
a major pharmacological target for the therapy of osteoporosis, it has been shown that PTH1-34 but not 23 
the PTH related peptide PTHrP1-36 − which activates the PTH receptor in a paracrine fashion − is capable 24 
of inducing persistent cAMP signaling [40]. Moreover, a PTH analog (M-PTH1-34) that produces a more 25 
sustained cAMP response than PTH1-34 has been shown to induce larger increases in trabecular bone 26 
volume and cortical bone turnover, although the responsible mechanisms have not been fully elucidated 27 
[60]. Similarly, vasopressin and oxytocin can both induce cAMP/PKA signaling upon binding to the V2 28 
receptor but only vasopressin leads to a strong antinatriuretic and antidiuretic effect [61-63]. Feinstein 29 
et al showed that this difference in signaling strength possibly results from different spatial signaling 30 
patterns induced by these two ligands [48]. These examples also suggest the possibility of designing 31 
GPCR agonists capable of preferentially inducing cell-surface vs. intracellular signaling. This might allow 32 
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developing a new generation of GPCR agonists with tailored biological effects, and thus, potentially 1 
improved efficacy and tolerability. 2 
More recently, our group took advantage of mice expressing a FRET sensor for cAMP to investigate 3 
cAMP signaling in intact ovarian follicles [64]. We found that activation of LH receptors with LH induces 4 
two waves of cAMP production that propagate within the follicles. Importantly, blocking receptor 5 
internalization prevented the second phase and partially inhibited the LH-induce resumption of meiosis 6 
in the oocyte [64]. These data indicate that LH receptor internalization plays an important role in 7 
mediating the biological effects of LH. Future studies appear required to further investigate the role of 8 
LH receptor signaling at intracellular sites in both female and male reproduction and its alterations in 9 
gonadal disorders. 10 
With the growing number of studies investigating GPCR signaling at intracellular sites, the physiological 11 
implications of this phenomenon are increasing. These include a role in insulin secretion for the GLP1 12 
receptor [49, 65], in renal water and sodium reuptake for the vasopressin V2 receptor [48] and in the 13 
excitability of cardiac neurons for the PACAP1 receptor [50]. 14 
Whereas receptor internalization has been mostly associated with prolonged cAMP signaling from 15 
intracellular sites, and thus mostly with slow biological effects, in the case of dopamine D1 receptors, it 16 
has been shown that these receptors are internalized very rapidly after agonist stimulation (within one 17 
minute) and that the resulting cAMP signaling from endosomal membranes increases neuronal 18 
excitability in striatal neurons [47]. 19 
So far, endosomal GPCR signaling has been mostly investigated in cellular models or using ex vivo 20 
preparations. Whereas these studies indicate that receptor internalization is required to mediate the 21 
biological effects of several hormones and neurotransmitters, further studies are required to investigate 22 
these processes in vivo.  Interestingly, two recent studies have provided first in vivo evidence for a 23 
relevant physiological role of endosomal GPCR signaling. A first study investigated the role of 24 
internalization of the neurokinin 1 (NK1) receptor, which mediates the effects of substance P, on pain 25 
sensing [66]. As a result of pain stimuli, substance P is released from the terminals of primary sensory 26 
neurons in the dorsal horn of the spinal cord, where it induces activation and internalization of NK1 27 
receptors expressed in second-order neurons [67, 68]. The results of the study indicate that inhibiting 28 
NK1 internalization and the resulting endosomal signaling attenuate nociception in vivo. This study also 29 
reports an innovative pharmacological strategy to selectively inhibit receptor endosomal signaling. For 30 
this purpose, the authors developed a cholestenol-conjugated antagonist, which accumulates in 31 
endosomes and is capable of inhibiting endosomal NK1 receptor signaling − which is required for 32 
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nociception − without affecting NK1 receptors at the cell surface. Similar results were obtained by the 1 
same group for the calcitonin receptor-like receptor, which binds the calcitonin-gene related peptide 2 
(CGRP), and is also implicated in pain transmission [69]. 3 
Altogether, these new findings reinforce the view that receptor internalization and signaling are 4 
inextricably linked and cooperate to mediate the effects of several hormones and neurotransmitters. 5 
While genetic defects in receptor trafficking have been associated with selected human diseases and we 6 
are beginning to explore the physiological implications of new exciting discoveries in this field, further 7 
studies are needed to investigate the involvement of receptor internalization and signaling at 8 
intracellular sites in a large repertoire of diseases. Furthermore, there is an urgent need in drug 9 
development to move away from oversimplified models of GPCR signaling to take into account the 10 
complex interplay between signaling and internalization. This might allow going far beyond the concept 11 
of either activating or inhibiting a receptor − on which current drugs are based − and design more 12 
selective drugs capable of modulating receptor signaling at the desired time and subcellular location. 13 
The clinician should keep an eye on these exciting developments, which might revolutionize the way of 14 
treating common diseases in the near future. 15 
 16 
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Practice points  29 
• GPCRs are the largest family of receptors and mediate the effects of several hormones and 30 
neurotransmitters 31 
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• GPCRs are major pharmacological targets (at least 30% of all drugs on the market target these 1 
receptors) 2 
• Prolonged stimulation with hormones or drugs leads to GPCR internalization 3 
• Receptor internalization serves different functions and has been unexpectedly shown to be 4 
required for the biological effects of hormones and neurotransmitters 5 
• Defects in receptor trafficking are involved in some genetic disorders and their involvement in 6 
common diseases needs to be further explored. 7 
• The new finding that GPCRs signal not only at the plasma membrane but also on membranes of 8 
endosomes and the Golgi/trans-Golgi network might allow to develop a new generation of drugs 9 
with improved efficacy and less side effects. 10 
 11 
Research agenda 12 
• Further explore the role of GPCR internalization in human physiology. 13 
• Investigate the involvement of receptor internalization and GPCR signaling on intracellular 14 
membranes in the pathogenesis of human diseases where GPCRs play an important role. 15 
• Develop new drugs capable of selectively activating or inhibiting GPCR at the cell surface vs. at 16 
intracellular sites or to modify GPCR internalization and/or intracellular trafficking. 17 
 18 
Figure legend 19 
Figure 1: The complex interply between GPCR signaling and innternalization. Binding of a ligand to a 20 
receptor (1) induces a first phase of G protein-dependent signaling at the plasma membrane (2). This is 21 
followed by GRK-mediated phoshorylation of the receptor and β-arrestin binding, which results in rapid 22 
desensitization. At the same time, β-arrestin promotes MAPK signaling (3). β-arrestin also induces 23 
receptor internalization via clathrin-mediated endoctosis (CME). The internalized receptor can induce a 24 
second phase of G protein-dependent signaling from either early endosomes or the Golgi/trans-Golgi 25 
network (4). This second signaling phase has been shown to be biologically relevant for a growing 26 
number of GPCRs. Afterwards, the receptor is either degraded in lysosomes or recycled back to the 27 
plasma membrane (5) to undergo another round of signaling.  28 
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